Jeff Reeves’s Strength in Numbers: 5 biotech stocks that could be the next big winners

Biotech stocks are some of the most exciting investments on Wall Street. When one company develops a successful treatment for a complex condition, shares can surge overnight and attract buyout interest from Big Pharma.

But when a drug trial fails, it can go down in flames. Case in point: Biotech giant Biogen BIIB, -4.48% imploded roughly 30% on Thursday after announcing it is canceling its Alzheimer’s drug efforts after poor drug trials. It fell again on Friday.

For those skittish of that kind of lurch, there are a few ETFs to diversify your investment and smooth out some of the bumps.

>>> Original Source <<<